Drug intelligence / Profile preview

dehydrated human amnion membrane

Development stage
Phase 3
Lead developer
MIMEDX
Modality
Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration
Topical, Implant
01

Overview

Dehydrated human amnion membrane (dHAM) is a tissue-based allograft derived from the innermost layer of the human placenta. It is processed using proprietary methods, such as the PURION® process, to create a stable, dehydrated graft that preserves the natural extracellular matrix (ECM), growth factors, and cytokines essential for tissue regeneration. dHAM serves as a biological scaffold that promotes cell migration and proliferation while providing a protective barrier for wounds. It is primarily utilized in the management of chronic, non-healing wounds like diabetic foot ulcers and venous leg ulcers, as well as in surgical settings to reduce inflammation and scarring, such as in postprostatectomy nerve protection and Mohs micrographic surgery reconstruction.

Brand names
EpiFixAmnioFix
Other names
dHAMdried human amnion graftdehydrated human amniotic membranedHACMdehydrated human amnion/chorion membrane
02

Targets

PDGF (Platelet-derived Growth Factor family)TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on dehydrated human amnion membrane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dehydrated human amnion membrane.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call